156 related articles for article (PubMed ID: 29452344)
1. Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.
Birkbak NJ; Li Y; Pathania S; Greene-Colozzi A; Dreze M; Bowman-Colin C; Sztupinszki Z; Krzystanek M; Diossy M; Tung N; Ryan PD; Garber JE; Silver DP; Iglehart JD; Wang ZC; Szuts D; Szallasi Z; Richardson AL
Ann Oncol; 2018 Apr; 29(4):903-909. PubMed ID: 29452344
[TBL] [Abstract][Full Text] [Related]
2. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.
Jin J; Zhang W; Ji W; Yang F; Guan X
Cancer Biol Ther; 2017 Jun; 18(6):369-378. PubMed ID: 28494179
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer.
Wang D; Feng J; Xu B
Future Oncol; 2019 Aug; 15(23):2779-2790. PubMed ID: 31293180
[No Abstract] [Full Text] [Related]
4. The identification of six risk genes for ovarian cancer platinum response based on global network algorithm and verification analysis.
Xing L; Mi W; Zhang Y; Tian S; Zhang Y; Qi R; Lou G; Zhang C
J Cell Mol Med; 2020 Sep; 24(17):9839-9852. PubMed ID: 32762026
[TBL] [Abstract][Full Text] [Related]
5. Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
Jacot W; Theillet C; Guiu S; Lamy PJ
Future Oncol; 2015; 11(4):557-9. PubMed ID: 25686112
[No Abstract] [Full Text] [Related]
6. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
7. Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
Telli M
Am Soc Clin Oncol Educ Book; 2014; ():e37-42. PubMed ID: 24857126
[TBL] [Abstract][Full Text] [Related]
8. [The prospects of DNA damage repair variants guiding platinum compounds in the treatment of triple negative breast cancer].
Wang X; Yue J; Kang YK; Gao SL; Yuan P
Zhonghua Zhong Liu Za Zhi; 2022 Jan; 44(1):68-72. PubMed ID: 35073650
[TBL] [Abstract][Full Text] [Related]
9. Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer.
Lin K; Ye D; Xie X
Int J Gynecol Cancer; 2008; 18(5):1007-12. PubMed ID: 18081788
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.
Jin Z; Wang W; Jiang N; Zhang L; Li Y; Xu X; Cai S; Wei L; Liu X; Chen G; Zhou Y; Liu C; Li Z; Jin F; Chen B
PLoS One; 2015; 10(7):e0130286. PubMed ID: 26196284
[TBL] [Abstract][Full Text] [Related]
11. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
12. Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials.
Guan X; Ma F; Fan Y; Zhu W; Hong R; Xu B
Anticancer Drugs; 2015 Sep; 26(8):894-901. PubMed ID: 26086398
[TBL] [Abstract][Full Text] [Related]
13. BLM promotes the activation of Fanconi Anemia signaling pathway.
Panneerselvam J; Wang H; Zhang J; Che R; Yu H; Fei P
Oncotarget; 2016 May; 7(22):32351-61. PubMed ID: 27083049
[TBL] [Abstract][Full Text] [Related]
14. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
Sharma P
Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
16. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
17. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
Haynes B; Gajan A; Nangia-Makker P; Shekhar MP
Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165561. PubMed ID: 31639439
[TBL] [Abstract][Full Text] [Related]
18. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
[TBL] [Abstract][Full Text] [Related]
19. APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC.
Malfatti MC; Gerratana L; Dalla E; Isola M; Damante G; Di Loreto C; Puglisi F; Tell G
J Exp Clin Cancer Res; 2019 Jul; 38(1):309. PubMed ID: 31307523
[TBL] [Abstract][Full Text] [Related]
20. Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?
Agrawal LS; Mayer IA
Clin Adv Hematol Oncol; 2014 Oct; 12(10):654-8. PubMed ID: 25658890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]